Literature DB >> 12949078

Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor.

Jie Liu1, Sándor Batkai, Pál Pacher, Judith Harvey-White, Jens A Wagner, Benjamin F Cravatt, Bin Gao, George Kunos.   

Abstract

Macrophage-derived endocannabinoids have been implicated in endotoxin (lipopolysaccharide (LPS))-induced hypotension, but the endocannabinoid involved and the mechanism of its regulation by LPS are unknown. In RAW264.7 mouse macrophages, LPS (10 ng/ml) increases anandamide (AEA) levels >10-fold via CD14-, NF-kappaB-, and p44/42-dependent, platelet-activating factor-independent activation of the AEA biosynthetic enzymes, N-acyltransferase and phospholipase D. LPS also induces the AEA-degrading enzyme fatty acid amidohydrolase (FAAH), and inhibition of FAAH activity potentiates, whereas actinomycin D or cycloheximide blocks the LPS-induced increase in AEA levels and N-acyltransferase and phospholipase D activities. In contrast, cellular levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) are unaffected by LPS but increased by platelet-activating factor. LPS similarly induces AEA, but not 2-AG, in mouse peritoneal macrophages where basal AEA levels are higher, and the LPS-stimulated increase in AEA is potentiated in cells from FAAH-/- as compared with FAAH+/+ mice. Intravenous administration of 107 LPS-treated mouse macrophages to anesthetized rats elicits hypotension, which is much greater in response to FAAH-/- than FAAH+/+ cells and is susceptible to inhibition by SR141716, a cannabinoid CB1 receptor antagonist. We conclude that AEA and 2-AG synthesis are differentially regulated in macrophages, and AEA rather than 2-AG is a major contributor to LPS-induced hypotension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949078     DOI: 10.1074/jbc.M306062200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  Cannabinoids cool the intestine.

Authors:  George Kunos; Pál Pacher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

2.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Cirrhotic cardiomyopathy: an endocannabinoid connection?

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 5.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 6.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

7.  Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids.

Authors:  Seyed Ali Gaskari; Hongqun Liu; Charlotte D'Mello; George Kunos; Samuel S Lee
Journal:  J Hepatol       Date:  2015-01-29       Impact factor: 25.083

Review 8.  Cannabinoid signalling and effects of cannabis on the male reproductive system.

Authors:  Mauro Maccarrone; Cinzia Rapino; Felice Francavilla; Arcangelo Barbonetti
Journal:  Nat Rev Urol       Date:  2020-11-19       Impact factor: 14.432

Review 9.  CB2 receptors in reproduction.

Authors:  M Maccarrone
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Does lipopolysaccharide-mediated inflammation have a role in OA?

Authors:  Zeyu Huang; Virginia Byers Kraus
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.